ABSTRACT
The immunologic and virologic activity of nevirapine in combination with two nucleosides (zidovudine [ZDV] and didanosine [ddI]) was evaluated in antiretroviral-naive patients with a CD4 count <200/mm3 or clinical AIDS. In all, 68 patients were enrolled in a 48-week double-blind, placebo-controlled trial. A group of 32 patients received ZDV + ddI + nevirapine, and 36 patients received ZDV + ddI. Primary efficacy parameters were the activity on HIV-1 RNA and on peripheral blood CD4+ cells, with differences between groups analyzed by the Wilcoxon's nonparametric two-sample test. Baseline RNA was high in both treatment groups (median values, 5.8 and 5.7 log10). RNA and CD4 responses were significantly higher with the triple combination (median RNA reductions, 2.69 versus 1.05 log10 at 24 weeks and 1.97 versus 1.20 log10 at 48 weeks; median CD4 increases, 81 versus 64 cells/mm3 at 24 weeks and 101 versus 27 cells/mm3 at 48 weeks). This study demonstrates that a triple combination of ZDV + ddI + nevirapine used as first-line regimen in antiretroviral-naive patients can induce sustained virologic and immunologic response in patients with low CD4 count or a previous diagnosis of AIDS.
Subject(s)
Acquired Immunodeficiency Syndrome/drug therapy , Anti-HIV Agents/administration & dosage , Adult , CD4 Lymphocyte Count , Didanosine/administration & dosage , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Nevirapine/administration & dosage , Zidovudine/administration & dosageABSTRACT
AIM OF THE STUDY: A multicentre randomized controlled trial to assess whether a short course of beta-interferon could reduce the rate of chronic evolution of acute hepatitis C, in line with recent observations, was started in Northern Italy in 1991. METHODS: Forty acute hepatitis C patients were randomized to receive natural beta interferon 3,000,000 international units intramuscularly three times a week for 4 weeks or symptomatic drugs, and were followed up for a median period of 22.5 months. RESULTS: The chronicity rate was 75% (15/20 patients) in the interferon-treated group, and 80% (16/20) in the untreated group. No difference in the duration of the acute phase of hepatitis was observed. Hepatitis C virus ribonucleic acid was determined in 21 cases and was positive in 19 cases at baseline and in 15/17 chronic and 1/4 non chronic cases at the end of follow-up. Side effects of therapy (flu-like syndrome in 40% of cases) were mild and short-lasting. No aminotransferase flare-ups were observed during treatment. CONCLUSIONS: Beta interferon at the suggested regimen is well tolerated but does not seem to significantly influence the natural course of acute hepatitis C.
Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C/drug therapy , Interferon-beta/therapeutic use , Acute Disease , Adolescent , Adult , Aged , Alanine Transaminase/analysis , Antiviral Agents/adverse effects , Chi-Square Distribution , Disease Progression , Drug Administration Schedule , Female , Follow-Up Studies , Hepatitis C/diagnosis , Hepatitis C Antibodies/analysis , Humans , Interferon-beta/adverse effects , Male , Middle Aged , Prognosis , RNA, Viral/analysis , Radioimmunoassay , Reference Values , Treatment OutcomeABSTRACT
We report the case of a young patient with typhoid fever who complained of pain in his left hypochondrium and shoulder and recrudescence of fever after 21 days of treatment with tiamphenicol and ampicilline. Ultrasonography lead to the diagnosis of splenic abscess; the patient was splenectomized and S. typhi was cultured from the pus. Splenic abscess was frequently observed before 1940; since then only 6 more cases are reported in literature.
